Electronic Resource
Management of bone disease in women after breast cancer.
| العنوان: | Management of bone disease in women after breast cancer. |
|---|---|
| المؤلفون: | Milat F., Vincent A.J. |
| بيانات النشر: | Taylor and Francis Ltd (E-mail: healthcare.enquiries@informa.com) United Kingdom 2015-11-03 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Breast cancer and osteoporosis are common conditions affecting women, particularly following menopause. With increasing breast cancer incidence, effects of therapies and decreasing mortality, issues relating to the preservation of bone health with breast cancer therapy have become a priority. Contributing factors to bone loss and fractures in women with breast cancer include tumor effects, estrogen deprivation secondary to breast cancer therapies (chemotherapy, ovarian ablation or aromatase inhibitors), natural menopause and secondary causes of bone loss, typically from concurrently prescribed medications. Management of osteoporosis and other survivorship care is complex, and a multi-disciplinary approach is recommended with assessment of risk factors for bone loss, optimization of bone health through lifestyle approaches and pharmacological interventions based on evidence-based algorithms. This review examines the pathophysiology of bone loss and gives guidelines for the management of bone disease in women with breast cancer.Copyright © 2015 International Menopause Society. |
| مصطلحات الفهرس: | glucocorticoid, risedronic acid/po [Oral Drug Administration], serotonin uptake inhibitor, tamoxifen/dt [Drug Therapy], menopause, ossification, osteoblast, osteoclast, osteolysis, osteoporosis/dt [Drug Therapy], priority journal, alendronic acid/po [Oral Drug Administration], antineoplastic agent/dt [Drug Therapy], aromatase inhibitor/dt [Drug Therapy], bisphosphonic acid derivative/dt [Drug Therapy], bisphosphonic acid derivative/iv [Intravenous Drug Administration], bisphosphonic acid derivative/po [Oral Drug Administration], cisplatin/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], denosumab/cm [Drug Comparison], denosumab/dt [Drug Therapy], denosumab/sc [Subcutaneous Drug Administration], doxorubicin/dt [Drug Therapy], estrogen, estrogen receptor alpha, exemestane, fluorouracil/dt [Drug Therapy], goserelin, heparin, ibandronic acid/po [Oral Drug Administration], methotrexate/dt [Drug Therapy], proton pump inhibitor, risedronic acid/cm [Drug Comparison], zoledronic acid/iv [Intravenous Drug Administration], article, bone density, bone disease, breast cancer/dt [Drug Therapy], cancer chemotherapy, cancer survivor, dual energy X ray absorptiometry, fracture, human, Article |
| URL: | Climacteric Click here for full text options LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2015 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/41126 Climacteric. 18 (Supplement 2) (pp 47-55), 2015. Date of Publication: 18 Dec 2015. 1369-7137 https://repository.monashhealth.org/monashhealthjspui/handle/1/41126 606668071 (Milat, Vincent) Department of Endocrinology, Monash Health, Clayton, VIC, Australia (Milat) Hudson Institute of Medical Research, Clayton, VIC, Australia (Vincent) Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, VIC 3168, Australia Vincent A.J.; Amanda.vincent@monash.edu 1305130462 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305130462 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |